Adamis Pharmaceuticals (ADMP) Gains Despite Mylan's Generic EpiPen
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Adamis Pharmaceuticals offers its own pre-filled epinephrine syringe, which is under review with the FDA. The company said its product would be 40% less than EpiPen.
ADMP is up 3.8% in pre-open trade Monday after gaining 25% on Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zynerba Pharma (ZYNE) Gains on Strong Volume
- Investors race back to U.S. bond funds at fastest clip in five months: ICI
- Viacom (VIAB) Sees Notable Upside
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Related EntitiesPre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!